In LUAD, successful engraftment correlated with larger tumor size (and relatedly higher T stage), a higher proportion of the genome with aberrant copy number, the presence of TP53 mutations and homozygous loss of a genomic region containing CDKN2A, CDKN2B and a cluster of type I interferon genes. Here, CDKN2A is linked to neoplasm.